Immatics Q2 FY26 net loss narrows to USD 71.2 million; revenue rises 92.59% to USD 10.4 million - IMTX News | RalliesImmatics Q2 FY26 net loss narrows to USD 71.2 million; revenue rises 92.59% to USD 10.4 million
I
IMTX• Q2 financial results
- Immatics posted Q2 net loss of USD 71.2 million, narrowing from USD 80.1 million a year earlier.
- Revenue rose 92.59% to USD 10.4 million, due to higher collaboration activity and cost share versus plan.
- Research and development expense climbed 38.33% to USD 71.1 million, driven by advancing clinical trials, particularly the SUPRAME study.
- Cash and financial assets fell to USD 448.2 million at June 30 from USD 534.7 million at Dec. 31; cash reach is projected into 2028.
Clinical program update
- SUPRAME enrollment remains on track for required randomizations by year-end.
- Final progression-free survival topline data are expected in H1 2027, with a BLA filing planned in 2027.
•
